Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period

AbstractBackground:Sublingual immunotherapy in patients with allergic rhinitis sensitised to house dust mites is safe, but its efficacy is controversial and sublingual immunotherapy withBlomia tropicalishas not yet been studied. This study sought to evaluate the efficacy of sublingual immunotherapy with house dust mite extract in children and adults with house dust mite allergic rhinitis over a period of two years.Methods:A prospective observational study was conducted of children and adults diagnosed with house dust mite allergic rhinitis who were treated with sublingual immunotherapy from 2008 to 2012. Total Nasal Symptom Scores, Mini Rhinoconjunctivitis Quality of Life scores and medication usage scores were assessed prospectively.Results:Thirty-nine patients, comprising 24 children and 15 adults, were studied. Total Nasal Symptom Scores and Mini Rhinoconjunctivitis Quality of Life scores dropped significantly at three months into therapy, and continued to improve. Medication usage scores improved at one year into immunotherapy.Conclusion:Sublingual immunotherapy with house dust mite extracts, includingB tropicalis, is efficacious as a treatment for patients with house dust mite allergic rhinitis.

Download Full-text

Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitised patients with allergic rhinitis: a systematic review and meta-analysis

Rhinology Journal ◽

10.4193/rhin20.588 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

J.Y. Kim ◽

D. Hwang ◽

M. Jang ◽

C.S. Rhee ◽

D.H. Han

Keyword(s):

Quality Of Life ◽

Systematic Review ◽

Allergic Rhinitis ◽

House Dust ◽

House Dust Mite ◽

Meta Analysis ◽

Clinical Effectiveness ◽

Nasal Symptom ◽

Dust Mite

Selecting an appropriate allergen-specific immunotherapy (AIT) regimen for polysensitised allergic rhinitis (AR) patients is challenging for clinicians. Although previous studies showed comparable effectiveness of single-allergen AIT with house dust mite (HDM) extract between monosensitised and polysensitised AR patients, there is no systematic review and meta-analysis demonstrating the comparable effectiveness of HDM AIT. In this meta-analysis, we analysed nine studies to compare the clinical effectiveness of HDM AIT. The primary outcome was nasal symptom score and secondary outcomes were medication and quality of life scores. The changes in nasal symptom score after HDM AIT did not significantly differ between monosensitised and polysensitised patients. The clinical effectiveness of HDM AIT regarding medication and quality of life score was not significantly different between monosensitised and polysensitised patients). In conclusion, single-allergen AIT with HDM extract showed comparable clinical effectiveness between polysensitised and monosensitised patients with AR.

Download Full-text

Quality of life improvement after a three-year course of sublingual immunotherapy in patients with house dust mite and grass pollen induced allergic rhinitis: results from real-life

Health and Quality of Life Outcomes ◽

10.1186/s12955-017-0764-z ◽

2017 ◽

Vol 15 (1) ◽

Cited By ~ 9

Author(s):

Silviya Mihaylova Novakova ◽

Maria Toncheva Staevska ◽

Plamena Ivanova Novakova ◽

Manuela Dimitrova Yoncheva ◽

Maria Stoykova Bratoycheva ◽

...

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

House Dust ◽

House Dust Mite ◽

Grass Pollen ◽

Sublingual Immunotherapy ◽

Real Life ◽

Dust Mite ◽

Life Improvement

Download Full-text

Treatment with SQ-HDM SLIT-tablet Improves Quality of Life in House Dust Mite Induced Allergic Rhinitis

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2017.12.524 ◽

2018 ◽

Vol 141 (2) ◽

pp. AB164

Author(s):

Eva Hammerby ◽

Sarah Buchs ◽

Karen S. Rance ◽

Dorte Rehm

Keyword(s):

Quality Of Life ◽

Allergic Rhinitis ◽

House Dust ◽

House Dust Mite ◽

Dust Mite

Download Full-text

The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study

The Journal of Laryngology & Otology ◽

10.1017/s0022215119000094 ◽

2019 ◽

Vol 133 (03) ◽

pp. 213-219

Author(s):

Y Tu ◽

H Zhang ◽

L Zhao ◽

P Jin ◽

X Zi ◽

...

Keyword(s):

Allergic Rhinitis ◽

House Dust ◽

House Dust Mite ◽

Analogue Scale ◽

Asthma Symptom ◽

Nasal Symptom ◽

Subcutaneous Immunotherapy ◽

Medication Score ◽

Dust Mite ◽

Symptom Scores

AbstractBackgroundSubcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials.MethodA total of 58 allergic rhinitis patients sensitised to house dust mites, with or without mild asthma, were included. Symptom score, medication score, visual analogue scale score and quality of life were assessed before and after 6, 12 and 24 months of subcutaneous immunotherapy.ResultsAfter two years of subcutaneous immunotherapy, asthma symptom scores nearly reached zero, whereas the scores remained higher for nasal symptoms. The changes in asthma symptom scores were markedly different (p < 0.05) and occurred faster than the changes in nasal symptom scores when compared between monosensitised and polysensitised groups. Significant reductions in visual analogue scale score and medication score were demonstrated after subcutaneous immunotherapy.ConclusionTwo-year subcutaneous immunotherapy with house dust mite vaccine is an effective treatment for both monosensitised and polysensitised allergic patients. The changes in asthma symptom scores were markedly different and occurred quicker than the changes in nasal symptom scores in Chinese house dust mite allergic patients.

Download Full-text